SrasV1, PascalFrancis, Curation, bibRecord, 000168

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds

Identifieur interne : 000168 ( PascalFrancis/Curation ); précédent : 000167; suivant : 000169

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds

Auteurs : F. Chen [Hong Kong] ; K. H. Chan [Hong Kong] ; Y. Jiang [Hong Kong] ; R. Y. T. Kao [Hong Kong] ; H. T. Lu [Hong Kong] ; K. W. Fan [Hong Kong] ; V. C. C. Cheng [Hong Kong] ; W. H. W. Tsui [Hong Kong] ; I. F. N. Hung [Hong Kong] ; T. S. W. Lee [Hong Kong] ; Y. Guan [Hong Kong] ; J. S. M. Peiris [Hong Kong] ; K. Y. Yuen [Hong Kong]

Source :

Journal of clinical virology [ 1386-6532 ] ; 2004.

RBID : Pascal:04-0464714

Descripteurs français

Pascal (Inist)
- Coronavirus, In vitro, Test sensibilité médicamenteuse, Sensibilité, Isolat clinique, Antiviral, Grave, Malade état grave, Aigu, Syndrome respiratoire aigu sévère, Voie respiratoire, Epidémie, Microbiologie, Virologie, Forme grave, Virus syndrome respiratoire aigu sévère.

English descriptors

KwdEn :
- Acute, Antiviral, Clinical isolate, Coronavirus, Critically ill, Drug susceptibility test, Epidemic, In vitro, Microbiology, Respiratory tract, Sensitivity, Severe, Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Virology.

Abstract

Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-la, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics.

A01	`01`	`1`		`@0 1386-6532`
A03		`1`		`@0 J. clin. virol.`
A05				`@2 31`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds`
A11	`01`	`1`		`@1 CHEN (F.)`
A11	`02`	`1`		`@1 CHAN (K. H.)`
A11	`03`	`1`		`@1 JIANG (Y.)`
A11	`04`	`1`		`@1 KAO (R. Y. T.)`
A11	`05`	`1`		`@1 LU (H. T.)`
A11	`06`	`1`		`@1 FAN (K. W.)`
A11	`07`	`1`		`@1 CHENG (V. C. C.)`
A11	`08`	`1`		`@1 TSUI (W. H. W.)`
A11	`09`	`1`		`@1 HUNG (I. F. N.)`
A11	`10`	`1`		`@1 LEE (T. S. W.)`
A11	`11`	`1`		`@1 GUAN (Y.)`
A11	`12`	`1`		`@1 PEIRIS (J. S. M.)`
A11	`13`	`1`		`@1 YUEN (K. Y.)`
A14	`01`			`@1 Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road @3 HKG @Z 1 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital @3 HKG @Z 2 aut. @Z 4 aut. @Z 7 aut. @Z 8 aut. @Z 9 aut. @Z 10 aut. @Z 11 aut. @Z 12 aut. @Z 13 aut.`
A14	`03`			`@1 Department of Biology, Hong Kong Baptist University, Kowloon Tong @3 HKG @Z 3 aut.`
A20				`@1 69-75`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 26272 @5 354000114050090120`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 24 ref.`
A47	`01`	`1`		`@0 04-0464714`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of clinical virology`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-la, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics.
C02	`01`	`X`		`@0 002A05C10`
C02	`02`	`X`		`@0 002B05C02J`
C03	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 In vitro @5 05`
C03	`02`	`X`	`ENG`	`@0 In vitro @5 05`
C03	`02`	`X`	`SPA`	`@0 In vitro @5 05`
C03	`03`	`X`	`FRE`	`@0 Test sensibilité médicamenteuse @5 06`
C03	`03`	`X`	`ENG`	`@0 Drug susceptibility test @5 06`
C03	`03`	`X`	`SPA`	`@0 Prueba sensibilidad medicamentosa @5 06`
C03	`04`	`X`	`FRE`	`@0 Sensibilité @5 07`
C03	`04`	`X`	`ENG`	`@0 Sensitivity @5 07`
C03	`04`	`X`	`SPA`	`@0 Sensibilidad @5 07`
C03	`05`	`X`	`FRE`	`@0 Isolat clinique @5 08`
C03	`05`	`X`	`ENG`	`@0 Clinical isolate @5 08`
C03	`05`	`X`	`SPA`	`@0 Aislado clinico @5 08`
C03	`06`	`X`	`FRE`	`@0 Antiviral @5 09`
C03	`06`	`X`	`ENG`	`@0 Antiviral @5 09`
C03	`06`	`X`	`SPA`	`@0 Antiviral @5 09`
C03	`07`	`X`	`FRE`	`@0 Grave @5 10`
C03	`07`	`X`	`ENG`	`@0 Severe @5 10`
C03	`07`	`X`	`SPA`	`@0 Grave @5 10`
C03	`08`	`X`	`FRE`	`@0 Malade état grave @5 11`
C03	`08`	`X`	`ENG`	`@0 Critically ill @5 11`
C03	`08`	`X`	`SPA`	`@0 Enfermo estado grave @5 11`
C03	`09`	`X`	`FRE`	`@0 Aigu @5 12`
C03	`09`	`X`	`ENG`	`@0 Acute @5 12`
C03	`09`	`X`	`SPA`	`@0 Agudo @5 12`
C03	`10`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 14`
C03	`10`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 14`
C03	`10`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 14`
C03	`11`	`X`	`FRE`	`@0 Voie respiratoire @5 67`
C03	`11`	`X`	`ENG`	`@0 Respiratory tract @5 67`
C03	`11`	`X`	`SPA`	`@0 Vía respiratoria @5 67`
C03	`12`	`X`	`FRE`	`@0 Epidémie @5 68`
C03	`12`	`X`	`ENG`	`@0 Epidemic @5 68`
C03	`12`	`X`	`SPA`	`@0 Epidemia @5 68`
C03	`13`	`X`	`FRE`	`@0 Microbiologie @5 69`
C03	`13`	`X`	`ENG`	`@0 Microbiology @5 69`
C03	`13`	`X`	`SPA`	`@0 Microbiología @5 69`
C03	`14`	`X`	`FRE`	`@0 Virologie @5 70`
C03	`14`	`X`	`ENG`	`@0 Virology @5 70`
C03	`14`	`X`	`SPA`	`@0 Virología @5 70`
C03	`15`	`X`	`FRE`	`@0 Forme grave @4 INC @5 79`
C03	`16`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @4 CD @5 96`
C03	`16`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @4 CD @5 96`
C03	`16`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virose @2 NM`
C07	`04`	`X`	`ENG`	`@0 Viral disease @2 NM`
C07	`04`	`X`	`SPA`	`@0 Virosis @2 NM`
C07	`05`	`X`	`FRE`	`@0 Infection @2 NM`
C07	`05`	`X`	`ENG`	`@0 Infection @2 NM`
C07	`05`	`X`	`SPA`	`@0 Infección @2 NM`
C07	`06`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 19`
C07	`06`	`X`	`ENG`	`@0 Respiratory disease @5 19`
C07	`06`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 19`
C07	`07`	`X`	`FRE`	`@0 Poumon pathologie @5 20`
C07	`07`	`X`	`ENG`	`@0 Lung disease @5 20`
C07	`07`	`X`	`SPA`	`@0 Pulmón patología @5 20`
C07	`08`	`X`	`FRE`	`@0 Appareil respiratoire @5 22`
C07	`08`	`X`	`ENG`	`@0 Respiratory system @5 22`
C07	`08`	`X`	`SPA`	`@0 Aparato respiratorio @5 22`
N21				`@1 264`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000822

Links to Exploration step

Pascal:04-0464714

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds</title>
<author><name sortKey="Chen, F" sort="Chen, F" uniqKey="Chen F" first="F." last="Chen">F. Chen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Chan, K H" sort="Chan, K H" uniqKey="Chan K" first="K. H." last="Chan">K. H. Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Jiang, Y" sort="Jiang, Y" uniqKey="Jiang Y" first="Y." last="Jiang">Y. Jiang</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Biology, Hong Kong Baptist University, Kowloon Tong</s1>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Kao, R Y T" sort="Kao, R Y T" uniqKey="Kao R" first="R. Y. T." last="Kao">R. Y. T. Kao</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Lu, H T" sort="Lu, H T" uniqKey="Lu H" first="H. T." last="Lu">H. T. Lu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Fan, K W" sort="Fan, K W" uniqKey="Fan K" first="K. W." last="Fan">K. W. Fan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Cheng, V C C" sort="Cheng, V C C" uniqKey="Cheng V" first="V. C. C." last="Cheng">V. C. C. Cheng</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Tsui, W H W" sort="Tsui, W H W" uniqKey="Tsui W" first="W. H. W." last="Tsui">W. H. W. Tsui</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Hung, I F N" sort="Hung, I F N" uniqKey="Hung I" first="I. F. N." last="Hung">I. F. N. Hung</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Lee, T S W" sort="Lee, T S W" uniqKey="Lee T" first="T. S. W." last="Lee">T. S. W. Lee</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Guan, Y" sort="Guan, Y" uniqKey="Guan Y" first="Y." last="Guan">Y. Guan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Peiris, J S M" sort="Peiris, J S M" uniqKey="Peiris J" first="J. S. M." last="Peiris">J. S. M. Peiris</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Yuen, K Y" sort="Yuen, K Y" uniqKey="Yuen K" first="K. Y." last="Yuen">K. Y. Yuen</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0464714</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0464714 INIST</idno>
<idno type="RBID">Pascal:04-0464714</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000822</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000168</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds</title>
<author><name sortKey="Chen, F" sort="Chen, F" uniqKey="Chen F" first="F." last="Chen">F. Chen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Chan, K H" sort="Chan, K H" uniqKey="Chan K" first="K. H." last="Chan">K. H. Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Jiang, Y" sort="Jiang, Y" uniqKey="Jiang Y" first="Y." last="Jiang">Y. Jiang</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Biology, Hong Kong Baptist University, Kowloon Tong</s1>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Kao, R Y T" sort="Kao, R Y T" uniqKey="Kao R" first="R. Y. T." last="Kao">R. Y. T. Kao</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Lu, H T" sort="Lu, H T" uniqKey="Lu H" first="H. T." last="Lu">H. T. Lu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Fan, K W" sort="Fan, K W" uniqKey="Fan K" first="K. W." last="Fan">K. W. Fan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Cheng, V C C" sort="Cheng, V C C" uniqKey="Cheng V" first="V. C. C." last="Cheng">V. C. C. Cheng</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Tsui, W H W" sort="Tsui, W H W" uniqKey="Tsui W" first="W. H. W." last="Tsui">W. H. W. Tsui</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Hung, I F N" sort="Hung, I F N" uniqKey="Hung I" first="I. F. N." last="Hung">I. F. N. Hung</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Lee, T S W" sort="Lee, T S W" uniqKey="Lee T" first="T. S. W." last="Lee">T. S. W. Lee</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Guan, Y" sort="Guan, Y" uniqKey="Guan Y" first="Y." last="Guan">Y. Guan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Peiris, J S M" sort="Peiris, J S M" uniqKey="Peiris J" first="J. S. M." last="Peiris">J. S. M. Peiris</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Yuen, K Y" sort="Yuen, K Y" uniqKey="Yuen K" first="K. Y." last="Yuen">K. Y. Yuen</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical virology</title>
<title level="j" type="abbreviated">J. clin. virol.</title>
<idno type="ISSN">1386-6532</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical virology</title>
<title level="j" type="abbreviated">J. clin. virol.</title>
<idno type="ISSN">1386-6532</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute</term>
<term>Antiviral</term>
<term>Clinical isolate</term>
<term>Coronavirus</term>
<term>Critically ill</term>
<term>Drug susceptibility test</term>
<term>Epidemic</term>
<term>In vitro</term>
<term>Microbiology</term>
<term>Respiratory tract</term>
<term>Sensitivity</term>
<term>Severe</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Virology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term>
<term>In vitro</term>
<term>Test sensibilité médicamenteuse</term>
<term>Sensibilité</term>
<term>Isolat clinique</term>
<term>Antiviral</term>
<term>Grave</term>
<term>Malade état grave</term>
<term>Aigu</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Voie respiratoire</term>
<term>Epidémie</term>
<term>Microbiologie</term>
<term>Virologie</term>
<term>Forme grave</term>
<term>Virus syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-la, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1386-6532</s0>
</fA01>
<fA03 i2="1"><s0>J. clin. virol.</s0>
</fA03>
<fA05><s2>31</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CHEN (F.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CHAN (K. H.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>JIANG (Y.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KAO (R. Y. T.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LU (H. T.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>FAN (K. W.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CHENG (V. C. C.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>TSUI (W. H. W.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>HUNG (I. F. N.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>LEE (T. S. W.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>GUAN (Y.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>PEIRIS (J. S. M.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>YUEN (K. Y.)</s1>
</fA11>
<fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Biology, Hong Kong Baptist University, Kowloon Tong</s1>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>69-75</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26272</s2>
<s5>354000114050090120</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0464714</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical virology</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-la, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02J</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>In vitro</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>In vitro</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>In vitro</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Test sensibilité médicamenteuse</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Drug susceptibility test</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Prueba sensibilidad medicamentosa</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Sensibilité</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Sensitivity</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sensibilidad</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Isolat clinique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Clinical isolate</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Aislado clinico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Grave</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Severe</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Grave</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Malade état grave</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Critically ill</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Enfermo estado grave</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Aigu</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Acute</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Agudo</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Voie respiratoire</s0>
<s5>67</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Respiratory tract</s0>
<s5>67</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Vía respiratoria</s0>
<s5>67</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Epidémie</s0>
<s5>68</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Epidemic</s0>
<s5>68</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Epidemia</s0>
<s5>68</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Microbiologie</s0>
<s5>69</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Microbiology</s0>
<s5>69</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Microbiología</s0>
<s5>69</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Virologie</s0>
<s5>70</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Virology</s0>
<s5>70</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Virología</s0>
<s5>70</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Forme grave</s0>
<s4>INC</s4>
<s5>79</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virose</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Viral disease</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virosis</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Infección</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>19</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>19</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>19</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>20</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>20</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>20</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Appareil respiratoire</s0>
<s5>22</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Respiratory system</s0>
<s5>22</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Aparato respiratorio</s0>
<s5>22</s5>
</fC07>
<fN21><s1>264</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000168 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000168 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:04-0464714
   |texte=   In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri